for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GW Pharmaceuticals PLC- ADR

GWPH.O

Latest Trade

127.44USD

Change

3.10(+2.49%)

Volume

617,180

Today's Range

123.70

 - 

130.49

52 Week Range

90.14

 - 

196.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
124.34
Open
124.51
Volume
617,180
3M AVG Volume
13.13
Today's High
130.49
Today's Low
123.70
52 Week High
196.00
52 Week Low
90.14
Shares Out (MIL)
370.62
Market Cap (MIL)
3,840.33
Forward P/E
-197.37
Dividend (Yield %)
--

Next Event

Q3 2019 GW Pharmaceuticals PLC Earnings Release

Latest Developments

More

GW Pharmaceuticals PLC Reports Q2 Financial Results

GW Pharmaceuticals Receives Positive CHMP Opinion For Epidyolex™ (Cannabidiol Oral Solution)

GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results For Epidiolex

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GW Pharmaceuticals PLC- ADR

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.

Industry

Biotechnology & Drugs

Contact Info

Sovereign House

Vision Park, Chivers Way

+44.1223.266800

https://www.gwpharm.com/

Executive Leadership

Geoffrey W. Guy

Executive Chairman of the Board

Justin Gover

Chief Executive Officer, Executive Director

James Julian Noble

Non-Executive Deputy Chairman of the Board, Senior Independent Director

Adam David George

Chief Financial Officer, Company Secretary, Director

Christopher John Tovey

Chief Operating Officer, Executive Director

Key Stats

1.64 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2019(E)

0.3K
EPS (USD)

2016

-3.650

2017

-6.950

2019(E)

-0.630
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.05
Price To Book (MRQ)
5.27
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.76
LT Debt To Equity (MRQ)
0.76
Return on Investment (TTM)
-22.65
Return on Equity (TTM)
-20.41

Latest News

Latest News

GW Pharma cannabis drug set to hit market following DEA nod

U.S.-listed shares of GW Pharmaceuticals rose 8 percent on Thursday as its marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential.

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's <GWPH.O> epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

GW Pharma wins U.S. approval for marijuana-derived epilepsy drug

An epilepsy treatment from GW Pharmaceuticals Plc on Monday secured an approval from the U.S. Food and Drug Administration, becoming the first cannabis-based drug to be approved in the country.

BRIEF-GW Pharmaceuticals Qtrly Loss Per ADS 312.0 Cents

* GW PHARMACEUTICALS PLC REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.

BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting

* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY

BRIEF-GW Pharma Says Presenting CBD-OS Product In Advisory Committee Meeting With FDA On April 19

* GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 - SEC FILING Source text: (https://bit.ly/2HK1BW3) Further company coverage:

BRIEF-GW Pharmaceuticals Announces Receipt Of Notices Of Allowance By USPTO

* GW PHARMACEUTICALS ANNOUNCES RECEIPT OF NOTICES OF ALLOWANCE BY THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR FIVE NEW EPIDIOLEX® (CANNABIDIOL) PATENTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-GW Pharmaceuticals Receives Orphan Drug Designation From EMA For Cannabidiol For The Treatment Of Tuberous Sclerosis

* GW PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY (EMA) FOR CANNABIDIOL FOR THE TREATMENT OF TUBEROUS SCLEROSIS

BRIEF-GW Pharma Says Mid Stage Study Of Seizures Drug Failed Main Goal

* GW PHARMACEUTICALS ANNOUNCES PRELIMINARY RESULTS OF PHASE 2A STUDY FOR ITS PIPELINE COMPOUND GWP42006

BRIEF-GW Pharmaceuticals Announces EMA Accepts Epidiolex Marketing Authorization Application For Review

* GW PHARMACEUTICALS ANNOUNCES THE EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS EPIDIOLEX® (CANNABIDIOL) MARKETING AUTHORIZATION APPLICATION (MAA) FOR REVIEW

BRIEF-GW Pharma Announces Acceptance Of NDA Filing For Epidiolex (Cannabidiol)

* GW PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF NDA FILING FOR EPIDIOLEX® (CANNABIDIOL) IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME AND DRAVET SYNDROME Source text for Eikon: Further company coverage:

BRIEF-GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.

* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.

BRIEF-GW Pharmaceuticals Announces Pricing Of Public Offering Of ADSs Raising Gross Proceeds Of $276 Million

* GW PHARMACEUTICALS PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS RAISING GROSS PROCEEDS OF $276 MILLION

BRIEF-GW Pharmaceuticals Announces Proposed Public Offering Of ADSs

* GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

Zogenix stock soars on epilepsy drug trial success

Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .

BRIEF-GW Pharmaceuticals reports Q3 results

* Gw Pharmaceuticals reports fiscal third quarter 2017 financial results and operational progress Source text for Eikon: Further company coverage:

GW to file cannabis drug as journal confirms epilepsy success

GW Pharmaceuticals is set to file its cannabis-derived drug with U.S. regulators imminently, following publication of detailed data on its success in fighting severe childhood epilepsy.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up